Madworks Coworking’s accelerator program on the University of Wisconsin-Madison campus, announces the second class of companies to begin the program this fall.
SnowShoe has been selected as one of nine startups to vie for a $100,000 investment from AOL co-founder Steve Case, during his Rise of the Rest tour stop in Madison. SnowShoe makes plastic widgets that conduct electricity, sending current from the user’s body to a smartphone or tablet touchscreen for two-factor identification. Rise of the Rest […]
Exact Sciences Corp. today announced that Group Health Cooperative will be the first health plan in Wisconsin to offer Cologuard® to its patients.
URP is pleased to welcome PSC Biotech to the Park. The California-based company, which specializes in making cancer-fighting drugs, will move into the former Mentor Biologics building and plans to hire over 100 positions. Drug production is slated to begin in 2015.
Madworks Coworking’s accelerator program, “Madworks at Campus” is offering grants of up to $4,000 for early stage startups to participate in a high energy 10-week lean startup class that provides structure and mentoring, helping these new businesses determine their viability in the marketplace.
Apply to pitch your company to the most active investors in the Midwest at the annual Wisconsin Early Stage Symposium!
Imbed Biosciences Inc., a Madison company with a novel biomaterials platform for wound dressings and surgical implants, has raised $683,000 of a planned $1 million funding round, according to filings with federal securities regulators.
Cellular Dynamics International Inc. said Thursday it has been granted a U.S. patent on the automated production of cells that can be grown into any of the more than 200 types of cells in the body.
The Morgridge Institute Medical Engineering team, responding to increased UW-Madison demand for microfluidics resources, has launched a new microfluidics foundry to build customized tools that bring biology down to the smallest possible scale.
Exact Sciences Corp. announced that Mayo Clinic will be the first health system to offer Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer.